Trial reportProstate cancer and prostatic diseases2013
Statin use and risk of prostate cancer and high-grade prostate cancer: results from the REDUCE study.
Trial report in Prostate cancer and prostatic diseases, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 4 syntheses or guidelines pooled it, 54 citations in OpenAlex.
- Radical prostatectomy versus deferred treatment for localised prostate cancer.The Cochrane database of systematic reviews · 2020Pooled it
- Assessment of biochemical recurrence of prostate cancer (Review).International journal of oncology · 2019Pooled it
- LDL-lowering therapy and the risk of prostate cancer: a meta-analysis of 6 randomized controlled trials and 36 observational studies.Scientific reports · 2016Pooled it
- Effect of statins type on incident prostate cancer risk: a meta-analysis and systematic review.Asian journal of andrologyPooled it
- Serum cholesterol and risk of high-grade prostate cancer: results from the REDUCE study.Prostate cancer and prostatic diseases · 2018Trial
- Statin Use, Serum Lipids, and Prostate Inflammation in Men with a Negative Prostate Biopsy: Results from the REDUCE Trial.Cancer prevention research (Philadelphia, Pa.) · 2017Trial
- Metabolic syndrome-like components and prostate cancer risk: results from the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study.BJU international · 2015Trial
- Alcohol intake increases high-grade prostate cancer risk among men taking dutasteride in the REDUCE trial.European urology · 2014Trial
- Obesity increases the risk for high-grade prostate cancer: results from the REDUCE study.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2014Trial
- Smoking and risk of low- and high-grade prostate cancer: results from the REDUCE study.Clinical cancer research : an official journal of the American Association for Cancer Research · 2014Trial
- Prostate Cancer and the Mevalonate Pathway.International journal of molecular sciences · 2024Review
- Atorvastatin Enhances the Efficacy of Immune Checkpoint Therapy and Suppresses the Cellular and Extracellular Vesicle PD-L1.Pharmaceutics · 2022Article
- Use of Hypolipidemic Drugs and the Risk of Second Primary Malignancy in Colorectal Cancer Patients.Cancers · 2022Article
- Association of Statin Use with the Risk of Incident Prostate Cancer: A Meta-Analysis and Systematic Review.Journal of oncology · 2022Article
- The role of metformin, statins and diet in men on active surveillance for prostate cancer.World journal of urology · 2022Review
- Article
- Statins in risk-reduction and treatment of cancer.World journal of clinical oncology · 2020Review
- Clinical association of metabolic syndrome, C-reactive protein and testosterone levels with clinically significant prostate cancer.Journal of cellular and molecular medicine · 2019Observational
- Statin and metformin therapy in prostate cancer patients with hyperlipidemia who underwent radiotherapy: a population-based cohort study.Cancer management and research · 2019Article
- Chemoprevention in Prostate Cancer: Current Perspective and Future Directions.Cold Spring Harbor perspectives in medicine · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStatins are associated with lower PSA levels. As PSA is the primary method for prostate cancer (PC) screening, this confounds any associations between statins and risk of being diagnosed with PC. Thus, we examined the association between statins and cancer and high-grade cancer in REDUCE, where biopsies were largely PSA-independent.
methodsPost-hoc secondary analysis of REDUCE, which was a prospective multinational randomized controlled trial of dutasteride vs placebo for 4 years among men aged 50-75 years with PSA of 2.5-10.0 ng ml(-1) and a negative biopsy at baseline, and included PSA-independent biopsies mandated at 2- and 4-years. Analyses were limited to men who underwent at least one biopsy while under study (n=6729). The association between baseline statin use and risk of overall, high-grade (Gleason ≥ 7) or low-grade (Gleason ≤ 6) PC vs no cancer was examined using multinomial logistic regression adjusting for age, race, baseline PSA, prostate volume, rectal examination findings, body mass index (BMI), comorbidities, smoking, alcohol intake and treatment arm.
resultsOf 6729 men who had at least one biopsy while on study, 1174 (17.5%) were taking a statin at baseline. Men taking statins were older, had lower PSA levels, higher BMI values and lower serum testosterone and dihydrotestosterone levels, though differences, were slight. Statin use was not associated with overall PC diagnosis (multivariable OR 1.05, 95% CI 0.89-1.24, P=0.54). When stratified by grade, statin use was not associated with low-grade (multivariable OR 1.03, 95% CI 0.85-1.25, P=0.75) or high-grade cancer (multivariable OR 1.11, 95% CI 0.85-1.45, P=0.46). The major limitation is the inclusion of only men with a negative baseline biopsy.
conclusionsAmong men with a negative baseline biopsy and follow-up biopsies largely independent of PSA, statins were not associated with cancer or high-grade cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.